Transdermal selegiline in HIV-associated cognitive impairment: pilot, placebo-controlled study.
The authors conducted a pilot randomized, double-blind, placebo-controlled clinical trial of the transdermal administration of selegiline in HIV+ patients to obtain preliminary data to assess its safety, tolerability, and impact on HIV-associated cognitive impairment. Both selegiline and placebo were well tolerated with few adverse events. Improvements favoring the selegiline group were suggested on single tests of verbal memory and motor/psychomotor performance, warranting a larger study.
Sacktor
N
N
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA. sacktor@jhmi.edu
Schifitto
G
G
McDermott
M P
MP
Marder
K
K
McArthur
J C
JC
Kieburtz
K
K
D000279:Administration, Cutaneous; D000328:Adult; D003072:Cognition Disorders / Q000821:virology*; D005260:Female; D006679:HIV Seropositivity / Q000503:physiopathology / Q000523:psychology*; D006801:Humans; D008297:Male; D011939:Mental Recall / Q000187:drug effects; D008875:Middle Aged; D008996:Monoamine Oxidase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D009043:Motor Activity / Q000187:drug effects; D010865:Pilot Projects; D010919:Placebos; D011597:Psychomotor Performance / Q000187:drug effects; D012642:Selegiline / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D014706:Verbal Learning
D008996:Monoamine Oxidase Inhibitors; D010919:Placebos; D012642:Selegiline